Superion Vertiflex is a minimally invasive implant used to treat certain patients with moderate lumbar spinal stenosis, a narrowing of the spinal canal that can cause leg, buttock, or groin pain when standing or walking. The small titanium spacer is placed between two adjacent bones in the lower spine to help create more room for compressed nerves, without removing bone or fusing the spine. Superion is not appropriate for every patient or every degree of spinal stenosis, and candidacy depends on symptoms, imaging findings, and a physician's evaluation. The physicians at Center for Spine & Pain Medicine (CSPM) evaluate each patient individually to determine whether Superion, or another treatment, may be a reasonable option.
Superion Vertiflex for Lumbar Spinal Stenosis
What Is Superion Vertiflex?
Superion Vertiflex is a minimally invasive, FDA-approved interspinous spacer implanted between two adjacent spinous processes (the bony points at the back of the spine) to help relieve leg, buttock, or groin pain caused by moderate lumbar spinal stenosis. It is a therapeutic device, not a diagnostic test, and is considered less invasive than traditional decompression surgery.
The device is a small titanium implant, available in several sizes, that is placed percutaneously through a narrow tube. Once positioned, it holds the treated spinal segment in a slightly more open position when the spine is upright, which may reduce pressure on nearby nerves during standing and walking. Superion does not involve removing bone or fusing vertebrae together, and it is designed to be used at one or two adjacent levels between L1 and L5.
How Does Superion Vertiflex Work?
Superion works by acting as a spacer between two spinous processes, limiting how far the treated segment can extend backward and helping maintain a slightly larger opening for the nerve pathways that become narrowed in spinal stenosis. This is sometimes called indirect decompression, since the device does not directly remove tissue pressing on a nerve.
Many people with lumbar spinal stenosis feel more comfortable bending forward or sitting, because those positions naturally open the spinal canal, and feel worse standing upright or walking, because extension narrows it further. By limiting extension at the treated level, Superion is intended to mimic some of that relief in a more sustained way. The device does not treat the underlying degenerative changes that caused the stenosis and does not restore disc height or reverse arthritis in the spine.
What Conditions May Superion Vertiflex Help Treat?
Superion Vertiflex is intended for skeletally mature patients with moderate lumbar spinal stenosis who have leg, buttock, or groin pain, numbness, or cramping (neurogenic intermittent claudication) that improves with bending forward, after at least six months of non-operative treatment. It is not indicated for every type or severity of spinal stenosis.
Under its FDA-approved indication, the device is intended for patients with radiographic evidence of moderate stenosis, defined as a 25 to 50 percent reduction in the central or nerve root canal, along with confirming findings such as nerve root compression or thickened ligament tissue on X-ray, MRI, or CT. Superion may be considered for stenosis at one or two adjacent levels from L1 to L5, with or without mild vertebral slippage (Grade 1 spondylolisthesis). It is not intended for patients whose primary complaint is low back pain without leg, buttock, or groin symptoms. Patients interested in learning more about spinal stenosis in general can review CSPM's conditions page.
Who May Be a Candidate for Superion Vertiflex?
A potential candidate for Superion Vertiflex is typically an adult with moderate lumbar spinal stenosis and leg, buttock, or groin symptoms that improve with flexion, who has completed at least six months of non-operative care and has imaging confirming an appropriate degree of stenosis. A physician evaluation is required to confirm candidacy.
Physicians generally review symptom pattern and duration, prior treatments such as physical therapy, medication, or injections, and MRI or CT imaging showing the degree and location of narrowing. Functional measures, such as the ability to sit comfortably and walk a reasonable distance, are also considered. Bone density may be assessed in some patients, since significant osteoporosis is a factor physicians weigh in candidacy. Ultimately, the treating physician determines whether an individual patient's diagnosis, anatomy, and treatment history support moving forward with Superion.
Who May Not Be a Candidate for Superion Vertiflex?
Some patients are not candidates for Superion Vertiflex. The device's labeling identifies exclusions that may include significant spinal instability, more than mild vertebral slippage, a fracture involving the spinous process or nearby bone, notable spinal curvature, severe osteoporosis, active infection, prior fusion or decompression at the same spinal level, or a body mass index above 40. This is not a complete list, and a full assessment of exclusions is determined individually by the treating physician and cannot be generalized to every patient.
What Happens Before the Procedure?
Before Superion is considered, a patient typically undergoes a consultation, review of prior imaging and treatment records, and a discussion of medications that may need to be adjusted beforehand, such as certain blood thinners. Insurance authorization is often required, since many plans require documentation of at least six months of prior non-operative treatment.
What Happens During the Procedure?
During the procedure, the patient is generally positioned face-down, and the physician uses fluoroscopic (X-ray) imaging to guide a narrow tube to the treatment level between two spinous processes. The Superion implant is then delivered through this tube and deployed to hold its position, after which imaging confirms placement before the tube is removed.
The procedure can be performed using local anesthetic with sedation or, in some cases, general anesthesia, depending on the patient and physician's approach. It does not require an open surgical incision or removal of bone. Because the device comes in multiple sizes, the physician selects the size that best fits the patient's anatomy at the time of the procedure.
Does Superion Vertiflex Hurt?
Patients commonly feel pressure or discomfort during placement despite anesthesia, along with soreness at the incision site for a period afterward. Pain tolerance varies between individuals, and any unusual or worsening pain, or new numbness or weakness, should be reported to the treating physician promptly.
How Long Does the Procedure Take?
Procedure length varies by individual anatomy and by whether one or two levels are treated. Preparation, anesthesia, and post-procedure observation time can add to the total time spent at the facility, so patients should expect their visit to take longer than the procedure itself.
How Long Is Recovery After Superion Vertiflex?
Recovery after Superion generally involves a period of activity modification while the surgical site heals, and many patients are able to walk on the same day or shortly after the procedure. Specific instructions for driving, work, exercise, and incision care vary by patient and should come from the treating physician rather than general guidance.
Because the procedure does not involve fusion or removal of bone, recovery is often described as shorter than recovery from open decompression surgery, though this varies by individual health status and the number of levels treated. Follow-up visits allow the physician to monitor healing and symptom response.
When Might a Patient Notice Results?
Some patients notice improvement in leg or back symptoms in the weeks following the procedure as swelling resolves and the implant stabilizes, while for others improvement develops more gradually. Relief is not guaranteed, and the degree and timing of improvement vary by patient.
How Long Might the Results Last?
Published follow-up data suggest that improvement can be maintained for a number of years in many patients, though results vary and long-term durability continues to be studied. In a study following the Superion arm of an FDA investigational device trial, researchers found that at 4 years after index procedure, 75 of 89 patients with Superion (84.3%) demonstrated clinical success on at least 2 of 3 ZCQ domains, among the subset of enrolled patients who completed 4-year evaluations. A related analysis of quality-of-life outcomes from the same FDA trial reported that mean scores improved from 29.4 ± 8.1 preoperatively to 41.2 ± 12.4 at 2 years and to 43.8 ± 11.6 at 5 years on a physical health quality-of-life measure. These findings describe group-level outcomes in study participants who remained available for follow-up, and they do not predict how long any individual patient's results will last.
How Much Does Superion Vertiflex Cost?
The out-of-pocket cost of Superion Vertiflex depends on multiple factors and cannot be stated as a fixed number without insurance verification. Costs may be affected by insurance network status, deductible, copayment, coinsurance, facility fees, imaging guidance, anesthesia, the number of levels treated, and the cost of the implanted device itself.
Because Superion involves an implanted device, costs can differ from injection-based treatments that do not involve hardware. Prior authorization and documentation of at least six months of non-operative treatment are commonly required by insurers before the procedure is approved.
Does Insurance Cover Superion Vertiflex?
Insurance coverage for Superion Vertiflex varies by plan and typically requires documentation of a confirmed diagnosis of moderate lumbar spinal stenosis, symptoms consistent with the device's intended use, and at least six months of prior non-operative treatment. Coverage is not guaranteed simply because a provider participates with an insurer.
Some plans classify interspinous spacers differently than others, and documentation requirements, medical necessity criteria, and prior authorization steps can vary widely. Even when a treatment is FDA approved, individual claims can still be denied based on plan-specific criteria. Patients are encouraged to review CSPM's financial policy page and verify their specific benefits before proceeding.
What Is the Success Rate of Superion Vertiflex?
There is no single universal success rate for Superion Vertiflex, since outcomes are reported differently across studies and follow-up periods. In the pivotal FDA trial comparing Superion to a control interspinous spacer, the overall composite clinical success rate at 24 months was 52.7% for Superion patients in the primary analysis population, a rate the FDA found to be statistically non-inferior to the control device. Longer-term follow-up in a subset of the same study population found that 75 of 89 patients (84.3%) demonstrated clinical success on at least 2 of 3 ZCQ domains at 4 years, a narrower measure that did not require the absence of any reoperation or complication. These figures come from specific study populations, definitions of success, and follow-up periods, and should not be generalized to predict an individual patient's outcome.
What Are the Risks and Side Effects?
As with any implanted device procedure, Superion Vertiflex carries risks in addition to possible benefit, and these should be weighed individually with a physician. Common temporary effects can include soreness at the incision site and mild swelling. Less common risks can include spinous process fracture, device migration, or persistence of symptoms requiring further treatment. Rare but serious complications can include infection, nerve injury, or dural leak (a tear in the tissue surrounding the spinal cord). Patients should promptly report fever, worsening pain, new weakness or numbness, or signs of infection at the incision site to their physician.
In the FDA pivotal trial, spinous process fracture was one of the more frequently observed device-related findings, occurring in a minority of patients in both study groups, and many of these fractures were found to be asymptomatic on follow-up imaging.
What Are the Alternatives to Superion Vertiflex?
Alternatives that may be considered instead of, or before, Superion Vertiflex include physical therapy, activity modification, medication management, epidural steroid injection, radiofrequency ablation, spinal cord stimulation, other interspinous devices, and, for appropriate candidates, surgical decompression or fusion. The appropriateness of any alternative depends on the specific diagnosis, severity of stenosis, and prior treatment history, and no single option is right for every patient.
How Does Superion Vertiflex Compare With Epidural Steroid Injection?
| Option | Common purpose | Typical candidate | Procedure type | Recovery considerations | Potential duration | Insurance considerations |
|---|---|---|---|---|---|---|
| Superion Vertiflex | Indirect decompression to relieve claudication symptoms from moderate lumbar spinal stenosis | Confirmed moderate stenosis with flexion-relieved leg, buttock, or groin symptoms after 6+ months of conservative care | Minimally invasive implant procedure | Activity modification during initial healing; individualized | Multi-year relief reported in some study populations; varies by patient | Requires documentation of imaging, symptoms, and prior conservative treatment |
| Epidural steroid injection | Reduce inflammation around compressed nerve roots | Nerve-related (radicular) leg pain, including some stenosis-related symptoms | Outpatient injection, no implant | Little to no downtime for most patients; individualized | Relief often temporary and may require repeat injections | Coverage varies; often used as part of conservative treatment before device-based options |
This table provides general information only and does not indicate that one option is superior for a given patient. A physician determines which treatment, if any, may be appropriate based on individual diagnosis and imaging.
When Should Someone Discuss Superion Vertiflex With a Pain Specialist?
Someone with leg, buttock, or groin symptoms consistent with spinal stenosis that has not improved after several months of conservative treatment may want to discuss Superion Vertiflex with a pain specialist as part of a broader conversation about treatment options. A consultation allows a physician to review prior treatment history, relevant imaging, and overall health to determine whether Superion, another treatment, or continued conservative care is appropriate. To schedule a consultation, visit CSPM's appointment page.
Frequently Asked Questions
Is Superion Vertiflex the same as spinal fusion?
No. Superion Vertiflex is an interspinous spacer that does not remove bone or permanently join two vertebrae together, while spinal fusion is a separate surgical procedure intended to stabilize the spine by joining segments. The two procedures are used for different situations and are not interchangeable. A physician determines which approach, if either, fits a patient's specific diagnosis and anatomy.
Can Superion be removed if it doesn't help?
The device can be removed if medically necessary, though whether removal is appropriate depends on the individual situation and should be discussed with the treating physician. Removal is not a routine or guaranteed option and involves its own considerations. Patients considering the procedure should discuss what would happen if symptoms do not improve as expected.
How many levels of the spine can Superion treat?
Superion is intended for use at one or two adjacent lumbar levels between L1 and L5 in appropriately selected patients. Treating more than two levels, or levels outside this range, falls outside the device's intended use. A physician determines the number and location of levels based on imaging and symptoms.
Will I need physical therapy after Superion Vertiflex?
Some patients are advised to pursue physical therapy or gradual activity progression after the procedure, though this is individualized and not a standard requirement for every patient. Any post-procedure therapy plan should come from the treating physician based on recovery and symptom response.
Is Superion Vertiflex covered the same way as spinal surgery?
Coverage criteria for Superion may differ from criteria for open decompression or fusion surgery, since insurers may classify and evaluate medical necessity differently depending on the procedure type. Documentation requirements, such as imaging and prior conservative treatment, are generally still required. Patients should verify their specific plan's coverage criteria before proceeding.
What if imaging shows severe, not moderate, spinal stenosis?
Superion's FDA-approved indication is specifically for moderate degenerative lumbar spinal stenosis, defined by a specific range of canal narrowing on imaging. Patients with severe stenosis outside this defined range may not be candidates for this particular device, and other treatment options may be more appropriate. A physician's review of imaging is required to determine which category applies.
Medical Review
Reviewed by Dr Sadiq Sohani, MD.
Sources
- Summary of Safety and Effectiveness Data (SSED), Superion InterSpinous Spacer, P140004 – U.S. Food and Drug Administration, 2015.
- Superion Interspinous Spacer Treatment of Moderate Spinal Stenosis: 4-Year Results – World Neurosurgery (PubMed), 2017.
- Interspinous Process Decompression Improves Quality of Life in Patients with Lumbar Spinal Stenosis – International Journal of Spine Surgery (PMC), 2018.